Affiliation:
1. Department of Nuclear Medicine, Clinique Sud Luxembourg, Vivalia, B-6700 Arlon, Belgium
Abstract
Molecular imaging with positron emission tomography is a powerful and well-established tool in breast cancer management. In this review, we aim to address the current place of the main PET radiopharmaceuticals in breast cancer care and offer perspectives on potential future radiopharmaceutical and technological advancements. A special focus is given to the following: the role of 18F-fluorodeoxyglucose positron emission tomography in the clinical management of breast cancer patients, especially during staging; detection of recurrence and evaluation of treatment response; the role of 16α-18Ffluoro-17β-oestradiol positron emission tomography in oestrogen receptors positive breast cancer; the promising radiopharmaceuticals, such as 89Zr-trastuzumab and 68Ga- or 18F-labeled fibroblast activation protein inhibitor; and the application of artificial intelligence.
Reference103 articles.
1. Cancer statistics;Siegel;CA Cancer J. Clin.,2018
2. American Cancer Society (2022, December 25). Breast Cancer Statistics|How Common Is Breast Cancer?. Available online: https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html.
3. FDG-PET/CT for Primary Staging and Detection of Recurrence of Breast Cancer;Groheux;Semin. Nucl. Med.,2022
4. Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer;Giuliano;Ann. Surg. Oncol.,2018
5. NCCN Guidelines Insights: Breast Cancer, Version 3;Goetz;J. Natl. Compr. Canc. Netw.,2019
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Role of 18F-NaF PET/CT in bone metastases;The Quarterly Journal of Nuclear Medicine and Molecular Imaging;2023-12